Report
Aelis Farma - Announced positive toxicology data for cannabis addiction compound AEF0117
*In vivo toxicology data required by regulatory agencies to enter AEF0117 in Ph3 trial following successful completion of Ph2b mid-2024.*The favorable safety profile observed in these non-clinical studies confirms the previously received positive feedback from an independent safety committee (DSMB) on the first 115 patients of the Ph2b study. These elements combined with the strong scientific rationale for targeting the CB1 receptor with their signaling-specific modulators makes us confident in a positive outcome of this trial.*No impact on investment case and valuation. We stick to our Buy rating and consider the Ph1/2 study readout for Down syndrome early 2024 to
Underlying
AELIS FARMA SA
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.